NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

NOVN.CH

127.1

-0.72%↓

LONN.CH

520.2

-0.42%↓

STMN.CH

88.94

+0.72%↑

Kodu・Aktsiate loetelu・Roche Holding AG

Roche Holding AG

Avatud

SektorTervishoid

371.4 1.2

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

362.8

Max

369.6

Põhinäitajad
By Trading Economics
Sissetulek	1.8B 5.5B
Müük	15B 31B
P/E Sektori keskmine	23.041 108.767
Dividenditootlus	2.63
Kasumimarginaal	17.892
Töötajad	103,249
EBITDA	5.1B 12B

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	2.63% 2.21%

Turustatistika
By TradingEconomics
Turukapital	5.3B 294B
Eelmine avamishind	370.2
Eelmine sulgemishind	371.4

Uudiste sentiment

By Acuity

100%

333 / 352 Pingereas Healthcare

Roche Holding AG Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

29. jaan 2026, 10:07 UTC

Tulu

Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength -- Update

29. jaan 2026, 07:07 UTC

Tulu

Roche Forecasts 2026 Growth, Helped by Strength of Drug Pipeline

18. nov 2025, 11:04 UTC

Suurimad hinnamuutused turgudel

Roche Shares Rise After Breast-Cancer Pill Shows Positive Results in Trial

23. okt 2025, 09:32 UTC

Tulu

Roche Raises Full-Year Earnings Outlook as U.S. Drug-Pricing Talks Continue -- Update

23. okt 2025, 05:54 UTC

Tulu

Roche Raises Full-Year Earnings Outlook

3. märts 2026, 07:22 UTC

Market Talk

Roche's Multiple Sclerosis Drug Safety Remains in Focus After Latest Trial -- Market Talk

2. märts 2026, 14:21 UTC

Market Talk

Roche's Multiple Sclerosis Drug Might Not Clear FDA Bar -- Market Talk

29. jaan 2026, 11:40 UTC

Market Talk

Tulu

Roche's Guidance Seems Less Conservative Than Expected -- Market Talk

29. jaan 2026, 06:05 UTC

Tulu

Roche Expects 2026 Core EPS to Increase in High-Single Digit Range at CER

29. jaan 2026, 06:04 UTC

Tulu

Roche Expects 2026 Mid-Single-Digit Range Sales Increase at Constant Currency

29. jaan 2026, 06:03 UTC

Tulu

Roche Issues 2026 View

29. jaan 2026, 06:02 UTC

Tulu

Analysts Saw 2025 Core EPS at CHF19.70

29. jaan 2026, 06:02 UTC

Tulu

Roche: 2025 Core EPS CHF19.46

29. jaan 2026, 06:01 UTC

Tulu

Analysts Had Seen 2025 Sales At CHF61.47B

29. jaan 2026, 06:01 UTC

Tulu

Roche 2025 Sales CHF61.52B

28. jaan 2026, 11:22 UTC

Tulu

Roche's Prospects in Weight-Loss Field to be in Focus -- Earnings Preview

27. jaan 2026, 11:31 UTC

Market Talk

Roche's Weight-Loss Study Results Seem Promising -- Market Talk

27. jaan 2026, 11:24 UTC

Market Talk

Roche Might Struggle to Leave Mark in Crowded Obesity Market With CT-388 -- Market Talk

27. jaan 2026, 09:30 UTC

Market Talk

Roche's CT-388 Could Compete With Lilly's Zepbound on Obesity Efficacy -- Market Talk

27. jaan 2026, 07:52 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Roche Obesity Study Data Look Encouraging -- Market Talk

16. jaan 2026, 17:03 UTC

Market Talk

All Eyes on Guidance for European Big Pharma Earnings Season -- Market Talk

12. jaan 2026, 14:50 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

Pharma Sector Can Spend Big on M&A -- Market Talk

22. dets 2025, 08:48 UTC

Market Talk

U.S. Administration's Deals With Big Pharma Unveil Pricing Uncertainty -- Market Talk

19. nov 2025, 12:47 UTC

Market Talk

Roche's Breast Cancer Drug Trial Results Surprise Positively -- Market Talk

10. nov 2025, 12:16 UTC

Market Talk

Tulu

Roche Results for MS-Treatment Candidate Look Encouraging -- Market Talk

23. okt 2025, 09:19 UTC

Market Talk

Tulu

Roche's Sales Slow, But Drug Pipeline Could Support Long-Term Growth -- Market Talk

23. okt 2025, 09:11 UTC

Market Talk

Tulu

Roche Sales Miss Driven by Underperformance of Key Drugs -- Market Talk

23. okt 2025, 05:09 UTC

Tulu

Roche 3Q Sales Up 6% At CER

23. okt 2025, 05:07 UTC

Tulu

Roche 3Q Sales CHF14.92B

23. okt 2025, 05:07 UTC

Tulu

Analysts Had Seen 3Q Sales At CHF15.17B

Võrdlus sarnastega

Hinnamuutus

Roche Holding AG Prognoos

Hinnangu Konsensus

By TipRanks

0 ratings

Osta

Hoia

Müü

Põhineb 0 analüütiku instrumendi Roche Holding AG aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

333 / 352 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Roche Holding AG

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. It has strategic discovery collaboration with Flare Therapeutics Inc. proteomic and mass spectrometry platform and expertise to discover novel small molecules aimed at transcription factor targets in oncology. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.